Navigation Links
Isis Pharmaceuticals to Present at Upcoming Investor Conferences
Date:4/10/2015

CARLSBAD, Calif., April 10, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the following investor conferences:

  • 14th Annual Needham Healthcare Conference on Wednesday, April 15, 2015 in New York, NY;
  • 40th Annual Deutsche Bank Health Care Conference on Thursday, May 7, 2015 in Boston, MA;
  • 2015 Bank of America Merrill Lynch Health Care Conference on Tuesday, May 12, 2015 in Las Vegas; and
  • 2015 UBS Global Healthcare Conference on Tuesday, May 19, 2015 in New York, NY.

The above listed dates are subject to change.  Details on presentation times or changes to presentation dates can be found on the Company's website.  Please check www.isispharm.com for the latest information.

A live webcast of the presentations will be available on the "Investors & Media" section of the Isis website.  The replays will be available within 48 hours and will be archived for a limited time. 

ABOUT ISIS PHARMACEUTICALS, INC.
Isis is exploiting its leadership position in RNA-targeted technology to discover and develop novel drugs for its product pipeline and for its partners.  Isis' broad pipeline consists of 38 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, including neurological disorders, and cancer.  Isis' partner, Genzyme, is commercializing Isis' lead product, KYNAMRO®, in the United States and other countries for the treatment of patients with homozygous FH.  Isis has numerous drugs in Phase 3 development in severe/rare diseases and cardiovascular diseases.  These include ISIS-APOCIIIRx, a drug Isis is developing and plans to commercialize through its wholly owned subsidiary, Akcea Therapeutics, to treat patients with familial chylomicronemia syndrome and partial lipodystrophy; ISIS-TTRRx, a drug Isis is developing with GSK to treat patients with the polyneuropathy and cardiomyopathy forms of TTR amyloidosis; and ISIS-SMNRx, a drug Isis is developing with Biogen to treat infants and children with spinal muscular atrophy, a severe and rare neuromuscular disease.  Isis' patents provide strong and extensive protection for its drugs and technology.  Additional information about Isis is available at www.isispharm.com.

ISIS PHARMACEUTICALS' FORWARD-LOOKING STATEMENT
This press release includes forward-looking statements regarding Isis' business and the therapeutic potential of Isis' technologies and products in development.  Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement.  Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs.  Isis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements.  Although Isis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis.  As a result, you are cautioned not to rely on these forward-looking statements.  These and other risks concerning Isis' programs are described in additional detail in Isis' annual report on Form 10-K for the year ended December 31, 2014, which is on file with the SEC.  Copies of this and other documents are available from the Company.

In this press release, unless the context requires otherwise, "Isis," "Company," "we," "our," and "us" refers to Isis Pharmaceuticals and its subsidiaries.

Isis Pharmaceuticals® is a registered trademark of Isis Pharmaceuticals, Inc.  Akcea Therapeutics™ is a trademark of Isis Pharmaceuticals, Inc.  Regulus Therapeutics™ is a trademark of Regulus Therapeutics Inc.  KYNAMRO® is a registered trademark of Genzyme Corporation.

Logo - http://photos.prnewswire.com/prnh/20130807/LA60006LOGO

 


'/>"/>
SOURCE Isis Pharmaceuticals, Inc.
Copyright©2015 PR Newswire.
All rights reserved

Related medicine technology :

1. Cumberland Pharmaceuticals To Present At The UBS Global Healthcare Conference In New York
2. Valeant Pharmaceuticals Announces Resignation of Dr. Laurence Paul from Valeants Board of Directors
3. DelMar Pharmaceuticals, Inc. Provides Corporate Update for the Quarter Ended March 31, 2013
4. Access Pharmaceuticals Reports First Quarter Results
5. The Zacks Analyst Blog Highlights: Genomic Health, Sanofi, Regeneron Pharmaceuticals, Amgen and Isis Pharmaceuticals
6. Actinium Pharmaceuticals Clinical Results to be Presented at 8th International Symposium on Targeted Alpha Therapy Conference
7. AcelRx Pharmaceuticals to Present at the UBS Global Healthcare Conference
8. Aveo Pharmaceuticals, Inc. Sued by Investor
9. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In AVEO Pharmaceuticals, Inc. To Contact The Firm
10. Atlantic Pharmaceuticals President Named Health Care Hero Finalist in Atlanta Business Chronicle for Drug Abuse Deterrent Technology
11. Valeant Pharmaceuticals To Present At 34th Annual Goldman Sachs Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/8/2020)... (PRWEB) , ... January 09, 2020 , ... ... now offering its partner practices a complimentary freezer program. The cryogenic freezer allows ... procedures. , The top stem cell and exosome biologics require cryogenic freezing. This ...
(Date:1/7/2020)... ... ... Myant Inc., the pioneers in Textile Computing™, will be showcasing a line-up ... (January 7-10, Las Vegas), including apparel from the Skiin Connected Health & Wellness line ... CES 2020 Innovation Awards. , While electrocardiography, or the study of the electrical activity ...
(Date:1/3/2020)... ... , ... ScreenPoint Medical’s Scientists who developed the Transpara AI ... faster, say a new international study by Google Health and Imperial College, London, ... including Hungary, Turkey, the USA and France. , The new study, published in ...
Breaking Medicine Technology:
(Date:1/10/2020)... ... January 10, 2020 , ... WellHaven Pet Health, a family of companion ... online community coming in February 2020, LEAD WELL with WOMEN. The community will be ... The vision of LEAD WELL with WOMEN is to empower women, engage all, connect, ...
(Date:1/10/2020)... Ore. (PRWEB) , ... January 10, 2020 , ... ... club located in Portland, Oregon, provides a friendly, non-intimidating environment for all women. ... introduce Balanced Habits to its current and prospective members. , For nearly ...
(Date:1/8/2020)... ... January 08, 2020 , ... Mirror Mirror ... 2019 Best of Memorial Readers’ Choice Awards. Located adjacent to Vitenas ... Best MedSpa in Memorial reflects Mirror Mirror Beauty Boutique’s commitment to the hottest ...
(Date:1/7/2020)... ... January 07, 2020 , ... G-CON Manufacturing, the leader ... company’s 200,000 sq. ft. manufacturing site in College Station, TX. The new facility, ... POD architectural, mechanical, electrical and automation fit out. , “This facility allows us ...
(Date:1/7/2020)... ... January 07, 2020 , ... CBD For The People ... while keeping the focus on the individual customer service experience. Transparency and integrity are ... and the profits second. By taking care of the people first, they know that ...
Breaking Medicine News(10 mins):